Mitsubishi UFJ Asset Management Co. Ltd. Grows Stock Holdings in Tempus AI, Inc. (NASDAQ:TEM)

Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in Tempus AI, Inc. (NASDAQ:TEM) by 255.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 67,200 shares of the company’s stock after acquiring an additional 48,300 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Tempus AI were worth $2,269,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Kovitz Investment Group Partners LLC acquired a new position in shares of Tempus AI in the third quarter valued at approximately $1,367,000. Victory Capital Management Inc. acquired a new position in Tempus AI in the 4th quarter valued at $216,000. China Universal Asset Management Co. Ltd. purchased a new position in Tempus AI during the 4th quarter worth $1,091,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Tempus AI in the 4th quarter worth $178,000. Finally, Captrust Financial Advisors purchased a new stake in shares of Tempus AI in the third quarter valued at about $2,726,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on TEM. Guggenheim reissued a “buy” rating on shares of Tempus AI in a report on Tuesday, February 25th. William Blair restated a “market perform” rating on shares of Tempus AI in a research note on Tuesday, February 25th. Wolfe Research cut Tempus AI from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 26th. Piper Sandler lowered their price target on shares of Tempus AI from $70.00 to $55.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Finally, Needham & Company LLC raised their price objective on shares of Tempus AI from $56.00 to $70.00 and gave the company a “buy” rating in a research note on Tuesday, February 25th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $61.18.

Tempus AI Stock Down 2.1 %

TEM stock opened at $47.22 on Wednesday. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. Tempus AI, Inc. has a 12 month low of $22.89 and a 12 month high of $91.45. The company’s 50 day simple moving average is $58.64 and its 200-day simple moving average is $51.56.

Insider Buying and Selling at Tempus AI

In other Tempus AI news, COO Ryan Fukushima sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $39.61, for a total transaction of $792,200.00. Following the sale, the chief operating officer now directly owns 982,442 shares of the company’s stock, valued at $38,914,527.62. This trade represents a 2.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jennifer A. Doudna sold 1,320 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $90.00, for a total transaction of $118,800.00. Following the completion of the transaction, the director now directly owns 36,011 shares of the company’s stock, valued at approximately $3,240,990. This represents a 3.54 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,598,969 shares of company stock worth $317,194,162.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.